Sekar Kathiresan
CEO
Sekar Kathiresan is a cardiologist and the CEO of Verve Therapeutics, a subsidiary of Eli Lilly. He led the recent groundbreaking study on a genetic editing treatment that significantly reduces LDL cholesterol levels, motivated by personal family health experiences with heart disease.
Global Media Ratings
Dominance
0.02%
Persistence
0 wks
Reach
2,175,768
Power
15,464$
Sentiment
8.00
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Brazil | 1 | 8.00 | 1.03% | +0% | 211,049,527 | 2,175,768 | $1,500,000 | 15,464$ |
| Totals | 1 | 211,049,527 | 2,175,768 | $1,500,000 | 15,464$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Brazil:
Sekar Kathiresan is the CEO of Verve Therapeutics and led the study on the genetic editing treatment.
8
John H P Alexander
Eric Rubin
J Michael Gaziano
Daniel Skovronsky
Kristy Faulkner
Erica Spatz
Alice Thomas
O Globo: Prevenção definitiva do colesterol? Cientistas mostram que pode ser possível